Case Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review

Case Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review

Epidermolysis bullosa acquisita (EBA) is a chronic, recurrent autoimmune subepidermal bullous disease characterized by the presence of autoantibodies targeting type VII collagen -- basement membrane zone antigen. Standard therapy for EBA includes a combination of systemic corticosteroids and dapsone...

Full description

Bibliographic Details
Main Authors: Konrad Szymański, Cezary Kowalewski, Ewelina Pietrzyk, Katarzyna Woźniak
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Immunology
Subjects:
epidermolysis bullosa acquisita
EBA
rituximab
infliximab
IVIG
inflammatory bowel diseases
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1214011/full

Similar Items

Similar Items